SEOUL, Jan. 3 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its antibody treatment candidate against COVID-19 has shown safety in its clinical trial. Celltrion said it has enrolled 24 healthy volunteers in its global phase one clinical trial and confirmed the safety, tolerability and pharmacokinetics of CT-P63. Separately, Celltrion said [...]
SEOUL, Dec. 7 (Korea Bizwire) — South Korean biotechnology firm Hyundai Bioscience Co. said Tuesday that the combination of its oral antiviral candidate and dexamethasone showed high efficacy in treating COVID-19 during animal testings. The company is currently re-purposing niclosamide-based CP-COV03 as a potential treatment for the COVID-19 virus. The investigative drug’s indication also includes [...]
SEOUL, Nov. 30 (Korea Bizwire) — Celltrion Healthcare Co., an affiliate of South Korean biopharmaceutical giant Celltrion Inc., said Tuesday it has inked a series of deals to supply its COVID-19 antibody treatment to nine European countries. Under the agreement, Celltrion Healthcare — which handles overseas business operations for Celltrion Inc. — will deliver 150,000 [...]
SEOUL, Feb. 5 (Korea Bizwire) — South Korea’s drug safety agency said Friday it has approved pharmaceutical giant Celltrion Inc.’s COVID-19 treatment candidate on several conditions. The conditional marketing authorization of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, marks the country’s first homegrown COVID-19 treatment. The Korean Ministry of Food and Drug Safety said CT-P59 [...]
TORONTO, Jan. 14 (Korea Bizwire) — Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), a developer of MedTech innovation, and Glow LifeTech Ltd. (“Glow”), a private company in which Relay holds a significant equity interest, are pleased to report on developments related to Glow’s MyCell Technology™ (“MyCell”). Glow LifeTech partner [...]
SEOUL, Jan. 13 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its COVID-19 treatment candidate reduces recovery time and the chance of a severe case developing. It was making public clinical data on the second-phase global trial study of the CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate. The firm earlier submitted [...]
SEOUL, Jan. 12 (Korea Bizwire) — South Korea’s pharmaceutical giant Celltrion Inc. said Tuesday that its anti-COVID-19 monoclonal antibody treatment has shown higher treatment efficacy compared to its two rival candidates. The Korean Ministry of Food and Drug Safety is currently reviewing conditional approval of Celltrion’s CT-P59, also known as Regdanvimab, a move that could [...]
SEOUL, Jan. 6 (Korea Bizwire) — South Korean biotech company GC Pharma said Wednesday it has completed phase two clinical trials of its plasma therapy treatment for the novel coronavirus. The plasma therapy, known as GC5131A, is a type of hyperimmune globulin drug that uses blood plasma taken from people who have fully recovered from [...]
SEOUL, Dec. 21 (Korea Bizwire) — South Korean drugmaker maker Daewoong Pharmaceutical Co. aims to launch a treatment drug for the novel coronavirus early next year, the company’s chief said Monday. Foistar, an oral protease inhibitor, is currently undergoing phase two clinical trial on COVID-19 patients with mild symptoms. The company aims to release the [...]
SEOUL, Nov. 18 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s coronavirus treatment is likely to file for emergency authorization use from local drug authorities next month, the company’s chief said Wednesday. CT-P59, anti-COVID-19 monoclonal antibody treatment, is currently undergoing a phase two clinical trial locally after successfully completing a phase one clinical trial [...]